New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:37 EDTADMSAdamas Pharmaceuticals presents positive results from ADS-5102 study
Adamas Pharmaceuticals presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia, a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 2/3 EASED study met its primary endpoint and the efficacy results of ADS-5102 were aligned across all outcome measures. In addition, ADS-5102 was generally well tolerated with reported adverse events consistent with Parkinson's disease and the known amantadine safety profile.
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ADMS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use